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ABSTRACT 
 
 Cancer stem cells (CSCs) can initiate and maintain tumours and may 
drive metastasis, recurrence and resistance to anti-neoplastic therapies. 
Recent evidence suggests that CSCs possess immunomodulatory 
capabilities that may enable them to evade host anti-cancer immunity 
to promote tumorigenicity. CSC immunological functions include 
evasion from immune clearance, induction of clonal anergy or deletion, 
and activation of regulatory immune cells. We recently identified 
Interleukin-8 as a crucial factor that sustains the stemness features of 
thyroid cancer (TC) cells through the induction, among the others, of 
OCT4 and SOX2 transcription factors. We generated OCT4/SOX2 
overexpressing TC cells and analysed their stemness and 
immunomodulatory properties. We confirmed that TC cell lines 
overexpressing OCT4/SOX2 showed, compared to control cells, an 
increase in stemness features. Accordingly, OCT4/SOX2 TC cells 
displayed increased tumour incidence and growth when injected at 
limiting number in mice compared to parental cells. Negative 
regulators of the immune system, including Programmed cell Death-
Ligands 1 and 2 (PD-L1/PD-L2) and the enzyme Indoleamine 2,3-
dioxygenase (IDO) are often “hijacked” by tumours to restrain the 
ability of the immune system to mount an effective anti-tumor 
response. Here, we show that OCT4/SOX2 expressing TC cells display 
increased PD1, PD-L1/2 and IDO expression both at mRNA and 
protein levels with respect to parental cells. Consistently, TC cells 
overexpressing OCT4 and SOX2, when co-cultured with lymphoid 
cells, caused a reduction of lymphocyte vitality compared to control 
cells. Thus, OCT4 and SOX2 are not only key regulators of stemness 
features but also of immunomodulatory properties of TC cells.  
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1.INTRODUCTION  
 
1.1 Thyroid cancer 
 
1.1 Thyroid cancer 
In the embryo, thyroid develops from the neural crest cells and the primitive 
pharynx. Thyroid is a butterfly-shaped endocrine gland located on the trachea 
in the anterior part of the neck. This endocrine gland consists of two distinct 
lobes connected by an isthmus. Two types of cells reside inside the gland: 
follicular cells and parafollicular C cells. The follicular epithelial cells, are 
involved in iodine uptake and are able to synthetize the thyroid hormones. 
Between follicular cells reside parafollicular C cells that produce calcitonin 
hormone. Thyroid carcinoma (TC) is the most common endocrine tumour 
(1.0-1.5%). The incidence of thyroid tumours on all new cancer cases in 
USA is 3.4%; it has been estimated that in 2017 there will be 56.870 new 
cases of TC per year 1. Ionizing radiations, genetic alterations, history of 
goitre, female gender and family history of thyroid disease, can be 
considered risk factors in the development of TC 1. In Italy, TC represents 
the second most common tumour in women under 45 years of age 1. Three 
principal pathological types of carcinoma arise from epithelial cells: papillary 
thyroid carcinomas (PTCs), follicular thyroid carcinomas (FTCs) and 
anaplastic thyroid carcinomas (ATCs). Instead, medullary thyroid carcinoma 
(MTC) arises from parafollicular cells. On the basis of the histological and 
clinical features we can divide thyroid carcinomas in well-differentiated, 
poorly-differentiated and undifferentiated/anaplastic types. Cancer is 
considered a multistep process in which the highly curable well-
differentiated carcinomas (WDTCs) evolve into aggressive anaplastic 
carcinomas (ATCs). Poorly-differentiated carcinomas (PDTCs) assume an 
intermediate position in this progression concept 2. WDTCs include papillary 
thyroid carcinomas (PTCs) and follicular thyroid carcinomas (FTCs), which 
are curable with radioiodine and exhibit a very good prognosis. PDTCs and 
ATCs are less common with respect to WDTCs and more aggressive 
exhibiting a bad prognosis. They are resistant to chemo- and radio-therapy 
and often develop metastases. PTCs represent 80% of all TC. PTCs usually 
present between 35 and 40 years of age and are three times more common in 
women than men; the peak of incidence is at 40-45 years. PTCs pathogenesis 
can be linked to radiation exposure; in fact 2-4% of the patients treated with 
ionizing radiations, mostly in the neck region, develops a differentiated 
thyroid carcinoma after about 20-30 years 3. Generally PTCs spread into 
lymphatic blood vessels and present regional node metastases in a significant 
proportion of the cases (2%). It is known that FTCs occur in areas of low 
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iodine concentration and are considered more aggressive than PTCs. FTCs 
are only rarely associated with radiation exposure. World Health 
Organization (WHO) defines FTCs by the presence of capsular and/or 
vascular invasion. Moreover, PTCs show typical nuclear features while FTCs 
do not. In FTCs the diffusion into lymph nodes is uncommon, while the 
invasion into blood vessels within thyroid gland is common. Usually FTCs 
develop metastasis more likely into distant organs than into regional lymph 
nodes. PTCs and FTCs, are WDTCs, have an excellent prognosis. Therapy 
for both PTCs and FTCs consists in the complete removal of the gland 
followed by a metabolic treatment with Iodine-131 (131I).  The patients show 
a survival rate at 10 years of 90-98%.  
The most aggressive type of thyroid cancer is the anaplastic thyroid cancer 
(ATCs). These carcinomas show highly abnormal cells and they are able to 
disseminate rapidly through other parts of the body (Figure 1). ATCs 
represent only about 1% of all TCs and usually spread beyond the thyroid by 
direct local extension. The presence of metastasis to regional nodes is 
common, but often their presence is not clearly detectable because extensive 
soft tissue invasion is present. Unfortunately, no effective therapy is known 
for ATCs, since these tumours show a chemo- and radio-resistant behaviour. 
The prognosis is very unfavourable, and the patients often die one year after 
diagnosis 4. Between WDTCs and ATCs there are the poorly differentiated 
PDTCs, rare aggressive thyroid tumours 5 (Figure 1). PDTCs show variable 
morphology including solid, trabecular, and insular components, the absence 
of conventional nuclear patterns of papillary carcinoma, and the presence of 
at least one of the following features: convoluted nuclei, mitotic activity, or 
necrosis 6. It is well known that the survival rate is poor among PDTCs 
patients than among those with WDTCs 7 8 9 (Figure 1).  
WDTCs generally have a favourable prognosis, but in ~5% of the cases they 
can progress to radioactive iodine-refractory (RAIR) tumours, which 
commonly lead to death within 5 years 10. RAIR tumours show the loss of 
their ability to take up 131I from the start of treatment or after previous 
evidence of uptake. This behaviour of malignant tissue is detected by a 
combination of imaging modalities, including an 131I whole body scan 
showing at least one lesion that does not takes up 131I, or clinical evidence 
that 131I is no longer providing benefit to the patient 11. Standard cytotoxic 
chemotherapy has limited efficacy, leading to the introduction in clinical 
trials of novel targeted therapies 10. 
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Figure 1: Molecular features of thyroid tumours (Modified from Williams 2002). 
 
Medullary thyroid carcinomas (MTCs) develop from parafollicular C cells of 
the thyroid and occur in about 5-7% of all TC. They can be sporadic or 
familial as part of the Multiple Endocrine Neoplasia type 2 syndromes. 
MEN2 syndromes are inherited cancer disorders including three types: 
MEN2A, that shows MTC, pheochromocytoma and parathyroid adenoma; 
MEN2B that shows MTC, pheochromocytoma and additional tumours such 
as neuromas and ganglioneuromas of the gut; Familial Medullary Thyroid 
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Carcinoma or FMTC whose only feature is MTC. MEN2 is inherited as a 
highly penetrant mendelian tract and this genetic transmission is due to gain 
of function mutations of the RET (REarranged during Transfection) gene. 
MTCs tend to metastasize to lymph nodes and distant organs, and their 
treatment consists in surgical removal of the lesion. MTCs are fairly resistant 
to most chemotherapy. 
 
1.2 Molecular genetics of thyroid tumors 
 
1.2.1 PTCs – papillary thyroid carcinomas 
PTCs include various histological subtypes: classical (CV), follicular (FV), 
tall cell (TCV) variant and other uncommon PTC variants. The development 
of PTCs is associated with different somatic mutations that include single 
nucleotide variants, small insertions and deletions, gene fusions and copy-
number alterations. A recent TCGA study characterized the genomic 
landscape of human PTCs. Single nucleotide variants were identified in 
MAPK-related genes, including BRAF, NRAS, HRAS and KRAS: mutations in 
these genes are mutually exclusive 12. BRAF mutations, observed in nearly 
40% of PTCs, have been associated with a more aggressive course of disease 
13. The RAS family of small GTPases (G proteins) includes KRAS, HRAS and 
NRAS, all of which are membrane-bound GTP/GDP-binding molecules. 
These proteins transfer signals from activated receptors to pathways that lead 
to the synthesis of key proteins involved in cell growth, proliferation and 
survival.  CV and TCV are mainly associated with BRAF mutations, while 
FV is associated with RAS mutations. A Glutamine for Valine substitution at 
residue 600 (V600E) in the activation segment of the kinase accounts for 
more than 90% mutations of BRAF in PTC 14-16. This mutation enhances 
BRAF activity through disruption of the auto-inhibited state of the kinase. 
Telomerase reverse transcriptase (TERT) promoter mutations, especially 
when co-existing with BRAF mutations, are associated with a poor prognosis 
in PTC. In addition, EIF1AX (eukaryotic translation initiation factor 1 A, X-
linked) was identified as a novel cancer gene involved in PTC initiation and 
progression. Chromosomal rearrangements and translocations also contribute 
to PTC pathogenesis. Gene fusions are mutually exclusive with each other 
and with BRAF, RAS, and EIF1AX mutations. Often the fusions are 
associated with young age at diagnosis. Different genes were fused with 
BRAF, some of which supported BRAF signal with expression and 
conservation of its kinase domain (MKRN1/BRAF); in other cases, there was 
an alternative activating mechanism. RET rearrangements have been reported 
in sporadic and radiation-associated PTCs 17. From a clinical point of view, 
PTCs could be classified into two molecular subtypes: BRAFV600E-driven 
tumours (BVL-PTCs) and mutant RAS-driven tumours (RL-PTCs), these 
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groups showing different genomic, epigenomic and proteomic profiles. The 
first group is dominated by BRAFV600E mutations, high levels of MAPK 
activation, loss of differentiation and high risk of recurrence; the second 
group is characterized by RAS mutations, relatively low levels of MAPK 
activation and dedifferentiation, and low risk of recurrence 18. 
  
1.2.2 FTCs – follicular thyroid carcinomas 
FTCs are the second most common type of thyroid malignancy, which 
accounts for 10-32% of cases of WDTCs 19. The most frequent genetic 
alterations in FTCs are RAS mutations (K, H and N) and the PAX8/PPARγ 
rearrangement. The prognostic value of RAS mutations is still unclear, 
although some evidence suggests that RAS-mutated FTCs may be at risk for a 
poor prognosis or distant metastasis. Moreover, regarding the prognostic 
effect of the coexistence of TERT promoter and RAS mutations, it has been 
recently demonstrated that their coexistence might increase the risk of 
disease-specific mortality and recurrence in WDTCs, including both PTCs 
and FTCs 20. 
 
1.2.3 PDTCs and ATCs – poorly differentiated thyroid 
carcinomas and anaplastic/undifferentiated thyroid 
carcinomas 
Most PDTCs and ATCs are thought to arise from preexisting PTCs. In fact, 
they often share a driver mutation. ATCs and PDTCs show higher number of 
mutations with respect to PTCs. BRAFV600E mutations are present in 
approximately 33% of PDTCs and 45% of ATCs, whereas NRAS, HRAS, or 
KRAS mutations occur in 28% and 24% of PDTCs and ATCs, respectively. 
RAS mutations are mutually exclusive with BRAF mutations and gene fusion. 
Also mutations in the PI3K/AKT/mTOR pathway are increased in ATCs (9%) 
and PDTCs (11%) with respect to PTCs  (1%) 21. These mutations occur in 
PTCs in a mutual exclusive manner with BRAF and RAS, while were closely 
related to RAS in PDTCs and ATCs. ATCs and PDTCs show an increase also 
in TERT promoter mutations with respect to PTCs 22. They are significantly 
associated with BRAF or RAS mutations, consistently with the proposed 
mechanism by which mutations in the promoter, by generating novel 
consensus motif for the ETS family of transcription factors, promote TERT 
overexpression in cells with constitutive activation of MAPK signalling. 
TP53 mutations were considered the principal hallmark of ATCs 23. 
Recently, it has been demonstrated that p53 mutations were common in 
ATCs but very rare in PDTCs. In ATCs, chromosomal rearrangement were 
absent, while they were frequent in PDTCs. Gene rearrangements did not 
overlap with BRAF, RAS, TSHR mutations 12. 
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1.3 Cancer stem cells 
  
1.3.1 Cancer stem cells properties  
It is well known that stem cells in normal tissues are able of renewing 
themselves and simultaneously generating committed progenitor cells. 
Asymmetric cell division affords this process. Committed progenitor can 
eventually give rise to a different tissue with specific functions 24. Recent 
data support the hypothesis that tumours contain a subpopulation of cells 
defined cancer stem cells (CSCs), which exhibit stem-like properties, such as 
the ability to self-renew, form tumourspheres in low adherence conditions, 
differentiate into various populations of cancer cells, and form new tumours 
in xenotransplantion experiments 25 26 (Figure 2). CSCs can originate both 
from the normal counterparts and from fully differentiated cells through a 
trans-differentiation process. CSCs were first identified in the hematopoietic 
system 27 more recently, however, they have also been discovered in solid 
tumours, including those arising in the breast, colon, brain, glioma, 
melanoma, prostate, lung, ovarian, renal cell and thyroid carcinomas 28-32. 
According to the CSC model, CSCs drive tumour initiation and growth and 
these cells are considered to be a cause of tumour relapse and disease 
progression, perhaps through their resistance to therapy and metastatic 
potential. Therefore, CSCs are currently extensively studied in various 
cancers. 
  
 
 
 
  
 
 
 
 
 
 
 
Figure 2: Characteristics of normal tissue stem cells and cancer stem cells. 
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1.3.2 Study and Characterization of CSCs 
CSC and normal stem cells share various important properties: unlimited 
capacity for self-renewal, asymmetric division, the ability to differentiate into 
several cell lineages and the intrinsic resistance against cytotoxic therapies 
through drug efflux mechanisms and slow cell cycling. To study CSCs is 
important their identification. The “gold standard” method to identify CSCs 
is to isolate them using biomarkers specific for the CSC population (cell 
surface marker), to test their sphere-forming ability in low-adherence 
condition and tumorigenicity at serial passaging, that is, CSCs derived from 
primary xenograft tumours should initiate tumour growth and give rise to 
secondary tumours. It is well accepted that there are several CSC markers in 
solid tumours (e.g. CD44high/CD24low for breast cancer, CD133+ for brain 
tumour and colon cancer, CD44+ for gastric cancer). There are several 
canonical markers that CSCs share with normal stem cell SOX2 (SRY-
related HMG-box gene 2), initially reported to be strongly linked with the 
inhibition of neuronal differentiation, has been shown to act as an important 
transcriptional factor to maintain the self-renewal capability of embryonic 
stem cells (ESCs). OCT4 (octamer-binding transcription factor 4), a member 
of the family of POU domain transcription factors that bind SOX2, 
represents also a key regulator essential for the pluripotency and self-renewal 
of ESCs. NANOG (Homeobox protein NANOG), a homeodomain-
containing protein, maintains pluripotency of mouse ESCs by inhibiting 
NFκB and cooperating with STAT3. ABCG2 is a member of the ATP 
binding cassette (ABC) transporters, which can pump a wide variety of 
endogenous and exogenous compounds out of cells.  ABCG2, widely 
expressed in stem cells, is also found to confer the “side population” 
phenotype.  Side population phenotype is recognized as a universal marker of 
stem cells. This feature can be assessed by using a discrimination assay, a 
flow cytometry method used to detect stem cells based on the dye efflux 
properties of ABC transporters. Nestin is an intermediate filament protein 
that is known as a neural stem/progenitor cell marker. Increased aldehyde 
dehydrogenase (ALDH) activity is another hallmark of CSCs measurable by 
the aldefluor assay. Cytosolic aldehyde dehydrogenases (ALDHs) are a 
group of enzymes involved in oxidizing a wide variety of intracellular 
aldehydes into their corresponding carboxylic acids. ALDH1, one of 19 
ALDH isoforms expressed in humans, is a marker of normal and malignant 
human mammary stem cells and a predictor of poor clinical outcome of 
breast cancer patients 33.  High ALDH1 activity has been used to define stem 
cell populations in many cancer types and has been described in primitive 
cells from multiple myeloma, acute myeloid leukemia, pancreatic, breast, and 
lung carcinomas 34. 
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1.3.3 Thyroid cancer stem-like cells  
Recent studies in thyroid cancer (TC) suggest that histological appearance 
and biological behaviour often show heterogeneity, with cells exhibiting 
distinct proliferative and differential capacities 33 35. 
The properties of thyroid CSCs remain not completely understood compared 
with that other of tumour types. A stem-like cell subpopulation, isolated from 
human TC specimens, featured growth in ultra-low adherence conditions in 
vitro, and cancer-initiating ability in vivo 32, 36-38. Moreover, clinical 
observations have revealed that CSC marker frequency in TC is related to 
adverse outcomes 39. Thus, CSCs have been indicated to play a crucial role in 
the malignant progression and therapeutic resistance of TC 40. Various 
research groups observed that more differentiated TC cell populations 
acquire CSC properties through EMT 41-43. These studies, therefore, raise the 
possibility that thyroid CSCs may arise from restricted progenitors or more 
differentiated cells that have acquired self-renewing capacity.  
Various human thyroid cancer stem cell (TC SC) markers have been 
proposed to distinguish CSCs from the bulk of tumour cells 44 45. However, 
the factors that specifically identify and regulate TC SCs are still undefined.  
Multiple cytokine networks are crucial in regulating CSC activity. Among 
these, Interleukin-8 (IL-8/CXCL8) is a key cytochine to maintain CSC 
functions in various tumours 46. IL-8 is a proinflammatory/chemoattractant 
cytokine, produced by leukocytes and other cell types (i.e., epithelial cells), 
that contributes to human cancer progression by sustaining cell proliferation, 
invasion, migration, angiogenesis and survival 47. IL-8 belongs to the CXC 
chemokine family and exerts its biological effects through two G protein-
coupled receptors, CXCR1 and CXCR2 47. We previously identified mast 
cell-derived IL-8 as a key paracrine factor that activates the epithelial-to-
mesenchymal transition (EMT) and increases the stemness features of TC 
cells 43. Consistently, previous studies demonstrated that the most common 
oncogenic drivers in TC (RET/PTC, HRASV12 or BRAFV600E) can activate an 
intrinsic inflammatory pathway responsible for the autocrine production of 
several chemokines/cytokines, including IL-8 48 49. We confirmed that IL-8 is 
expressed by human TC specimens and TC-derived cell lines. We showed 
that IL-8 production and CXCR1/2 expression are enriched in TC SCs with 
respect to the bulk of TC cells 50. Thus, IL-8 can be provided by both TC 
stroma and epithelial cells. The IL-8/CXCR1 circuit is crucial for 
maintenance of the stemness features and tumour-initiating ability of TC 
cells 50.  
 
1.3.4 CSC transcription factors  
In many human cancers OCT4, NANOG, and SOX2 have been found to be 
up-regulated, including oral squamous cell carcinoma 51, prostate cancer 52, 
and breast cancer 53. OCT4 has been shown to be up-regulated in additional 
 12 
cancers, including murine Lewis lung carcinoma 54, bladder cancer 55, and 
seminoma 56. NANOG and SOX2 have been found up-regulated in cases of 
human somatic tumours. The expression levels of OCT4, NANOG, and 
SOX2 mRNA transcripts, which are detected in tumour cells and CSC 
niches, are usually higher than those of non-tumour tissue. They are also 
more frequently overexpressed in poorly-differentiated tumours than in well-
differentiated tumours 53. In fact, the expression levels of pluripotent factors 
can decrease with the differentiation of the cells. The mechanism by which 
OCT4, SOX2 and NANOG act in CSCs is in part different in Embryonic 
Stem Cells (ESCs). Although CSC and ESC share the property of self-
renewal, ESCs emphasize differentiation, whereas CSCs emphasize 
proliferation. OCT4, NANOG, and SOX2 together maintain the repression of 
lineage-specific differentiation in ESCs. However, in CSCs, the 
overexpression of OCT4, NANOG, and SOX2 modulates signalling 
pathways to inhibit apoptosis 57. Consistently with the central role of OCT4 
and SOX2 in other CSC models, we found that thyrospheres, enriched in 
stem-like cells, expressed significantly higher mRNA and protein levels for 
the stemness markers OCT4, SOX2 and NANOG than adherent cells. The 
expression of SOX2 and OCT4 was efficiently induced by IL-8 in TC cell 
lines. Furthermore, IL-8 was able to activate in TC cell lines the stemness 
reporter SORE6 58 in which six repeats of a SOX2/OCT4 response element 
from the proximal human NANOG promoter 59 drives the expression of the 
mCherry reporter gene 50. 
 
1.4 CSC and immune-surveillance 
The immune system plays a key role in the surveillance against the tumours. 
Three main mechanisms are involved in this activity. First, elimination and 
suppression of viral infection are able to protect the host from virus-induced 
tumours. Second, the elimination of pathogens and resolution of 
inflammation can prevent the establishment of an inflammatory environment 
that promotes tumorigenesis 60. Third, the immune system is able to identify 
and eliminate tumour cells on the basis of their expression of tumour–
specific antigens or molecules induced by cellular stress 61. The third process 
is identified to as tumour immune-surveillance, whereby the immune system 
recognizes cancerous and/or precancerous cells and eliminates them before 
they can evolve in a tumour. Despite tumour immune-surveillance, tumours 
develop in the presence of a functioning immune system 60. 
In the interaction of host with tumour cells, three essential phases have been 
proposed: elimination, equilibrium and escape (Figure 3) 62. In the first 
phase, the immune system detects and eliminates tumour cells. During 
elimination all tumour cells can be cleared to obtain complete elimination 
phase or only a portion of tumour cells can be eliminated to obtain an 
incomplete elimination phase. In the case of partial tumour elimination, a 
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temporary state of equilibrium can then develop between the immune system 
and the developing tumour. It is possible that during this period tumour cells 
either remain dormant or continue to evolve, accumulating further changes 
(such as DNA mutations or changes in gene expression) that can modulate 
the tumour-specific and stress-induced antigens. This process allows the 
immune system to exploit a selective pressure by eliminating susceptible 
tumour clones where possible.  
 
 
 
Figure 3: Immune system continually recognizes and eliminates cancerous cells. The 
mutated cells, when evolving in precancer and cancer cells, escape immune-surveillance by 
generating immunosuppressive mechanisms. 
 
Using pressure selection mechanism, the immune system controls tumour 
progression, but sometimes, the immune response fails to completely 
eliminate the tumour selectioning tumour cell variants that are able to resist, 
avoid, or suppress the anti-tumour immune response, leading to the escape 
phase. During the escape phase, the immune system is not able to suppress 
tumour growth, and the tumours progressively emerge (Figure 3) 62. 
The immune system consists of various cell types able to mount both innate 
and adaptive immunity against pathogens. As an important component of 
adaptive immunity, T cell activation requires three signals 63. Signal 1 is 
acquired through the interaction between T cell receptor (TCR) and peptide-
loaded major histocompatibility complex (MHC) molecules. Signal 2 is 
induced through the interaction between co-stimulatory molecules on 
antigen-presenting cells (APC) and their receptors on T cells, thus enhancing 
T cell activation. Signal 3 is mediated by cytokines, such as IL-2 to promote 
Carcinogenesis	
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	cell	
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T cell proliferation. Co-stimulatory molecules are the most well-studied 
molecules and fall into immunoglobulin  super family members, including 
B7 family and tumour necrosis factor (TNF) family proteins. In order to limit 
immune response, co-inhibitory molecules are coopted. The immune 
inhibitory pathways is crucial for maintaining self-tolerance are hijacked 
from tumour cells to escape immune system control 64. Immune system 
normally is able to remove cancer cells from our body. However, many 
patients develop immune tolerance to tumour cells through up-regulation of 
immune regulatory molecules, release of immune suppressive factors in the 
tumour microenvironment and/or recruitment of regulatory/suppressive cells 
that impede the function of other fully activated effector immune cells 65. 
Cancer cells express many antigens that can be recognized and presented to T 
cells, leading to T cell activation and elimination of the tumour cells. This T 
cell immune response is modulated by negative regulatory molecules such as 
the immune checkpoint molecules such as PD-1, PD-L1, PD-L2, and IDO. 
Deregulation of these molecules in the tumour leads to tolerance of the 
tumour by immune system and cancer escape from surveillance 64. It has 
been observed that inhibitory ligands and receptors are usually overexpressed 
in cancer cells or their microenvironment. Inhibition of these immune 
checkpoints releases the brakes on the immune system, resulting in antigen-
specific-T-cell responses. Programmed Death-1 (PD-1) is a member of CD28 
family expressed on T cells PD-1 inhibits their survival, proliferation and 
immune function through interaction with its ligands PD-L1 and PD-L2. 
Interactions between PD-1 and PD-L1 attenuate immune response and serve 
to protect tumour cells from cytotoxic T cells. Indoleamine 2,3-dioxygenase 
(IDO) is the first and rate-limiting enzyme of tryptophan catabolism through 
the kynurenine pathway, thus causing depletion of tryptophan which can 
cause halted growth of microbes as well as T cells. It has been shown that 
IDO permits tumour cells to escape the immune system by depletion of L-
tryptophan in the microenvironment of cells and by production of the 
catabolic product kynurenine, which selectively impairs the growth and 
survival of T cells 64. 
 
1.4.1 Immunomodulatory properties of cancer stem cells 
Recent studies revealed that CSCs show immune-privileged phenotype with 
respect to normal stem cells 66. At least this has been shown to be the case for 
two types of cancers: melanoma and glioma. 
Melanoma CSCs have been identified as ATP-binding cassette sub-family B 
member 5 (ABCB5)-positive cells 67. Specifically, the melanoma CSCs 
ABCB5+ positive cells had significantly lower expression of MHC class I 
compared with the bulk of melanoma cells. In addition, ABCB5+ CSCs show 
an increase in the PD-L1 expression by compared with the bulk (ABCB5-) 
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melanoma cells. These evidences suggest a lower ability of CSCs to induce 
an immune response compared with the bulk of the tumour 67. 
Like many other types of cancer, the glioma microenvironment becomes 
immune suppressive, thus functionally inhibiting or inducing apoptosis of 
primed CD8+ cytotoxic T-cells 68. In addition, there is increased recruitment 
of other immune suppressive cells like FOXP3+ regulatory T-cells 69. 
Importantly, several studies have shown that this suppressive effect is 
especially exerted by glioma CSCs 66. Interestingly, when breast cancer cells 
were induced to go through EMT process under the influence of the 
transcriptional factor Snail, an EMT inducing gene, they promoted the escape 
of breast cancer cells from lysis mediated by CD8+ cytotoxic T cells 70. This 
further supports the role of CSCs in the immune escape of breast cancer. This 
effect is not limited to breast cancer but was also found to be relevant to 
melanoma. Melanoma cells induced to undergo EMT under the influence of 
Snail generated FOXP3+ Treg cells and impaired the maturation of dendritic 
cells both in vivo and in vitro 71. Collectively, the above data support that 
EMT, a process that enrich for CSCs, exhibits immunomodulatory 
properties. 
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2. AIM OF MY STUDY  
 
The aggressive features observed in many tumours have been attributed to a 
specific cell population that exhibits stem cell-like properties, defined as 
cancer stem cells (CSCs). These features include tumorigenic activity, 
recurrence, resistance to chemo- and radio-therapy, capacity to form 
metastasis.  
TC is not an exception in this regard, as a CSC population (TC SC) has been 
identified also in this type of cancer, based upon the stemness features of 
these cells, including the ability to form tumours in serial transplantation 
experiments. While in other cancer types the CSC population has been 
identified and isolated thanks to specific membrane markers, the TC SC 
population is still uncharacterized. Many reports indicate that TC cells 
acquire stemness features through the epithelial-to-mesenchymal transition 
(EMT) process. Thus, factors that promote EMT can also trigger stemness. 
According with this concept, we recently identified Interleukin-8 (IL-
8/CXCL8) as a crucial paracrine/autocrine factor that induces EMT and 
increases stemness features of TC cells. In fact, IL-8 induced a persistent 
increase in the SLUG transcription factor, a master regulator of EMT. This, 
in turn, activated EMT and enhanced stem-like features of TC cells. In fact, 
we identified OCT4 and SOX2, among the others, as important genes whose 
mRNA and protein levels could be increased by IL-8 treatment, in a SLUG-
dependent manner 43 50.  
Here, we investigated the features of TC stem-like cells (TC SCs). To this 
aim, we set up various cellular systems with enhanced stemness features. We 
established TC cultures ectopically co-expressing the OCT4/SOX2 
transcription factors. We also used SLUG- or IL-8-overexpressing/silenced 
TC cells that were previously developed and characterized in our laboratory.   
We analysed the stemness/malignant features of OCT4/SOX2 TC cells by 
evaluating their sphere-forming and self-renewal efficiency, their ability to 
proliferate, survive, migrate and form tumours into immunodeficient animal 
models at limiting numbers. 
 Moreover, we characterized the immunosuppressive features of different TC 
cell lines, derived from human TC of different histology (including PTCs and 
ATCs), by evaluating the levels of immunomodulatory molecules and the 
ability to suppress lymphocyte vitality. We also assessed the impact of 
stemness on this immune phenotype by comparing the immunosuppressive 
ability of parental TC cells with the same cells featuring enhanced stemness 
features, including OCT4/SOX2-, SLUG- and IL-8-transfected cells.  
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3. MATERIALS AND METHODS  
 
3.1 Cell cultures 
Nthy-ori (or Nthy-ori 3.1) are human SV-40 immortalized thyroid epithelial 
cells. TPC-1 (RET/PTC1), BcPAP (Braf V600E and P53D259Y) are derived from 
human thyroid papillary carcinomas; 8505c (BRAFV600E and P53R248G), 
SW1736 (BRAFV600E), FRO (BrafV600E), and BHT-101 (BRAFV600E), Cal62 
(KRASG12R) are derived from anaplastic thyroid carcinomas. All these cell 
lines grew in DMEM (Dulbecco’s Modified Eagle Medium), supplemented 
with 10% fetal bovine serum, 1% penicillin/streptomycin and 1% glutamine 
(Life Technologies Inc., Pasley, PA); they were kept in incubator at 37˚C in 
humidified atmosphere containing 5% CO2 50. 
 
3.2 Generation of stable clones 
To generate stable clones, 850-5C and TPC-1 cells at approximately 70% 
confluence were  transfected with pBabe-puro empty vector or co-transfected 
with pBabe-puro and pMXs-hOCT4 (# 17964) and pMXs-hSOX2 vectors (# 
17965) (Addgene) by electroporation (Transfection System for 
Electroporation, life technologies). Stably transfected cells were selected 
adding puromycin (500 ng/ml) to culture dishes two days after transfection. 
Puromycin-resistant colonies were then harvested and analysed for mRNA 
and  protein expression and biological activity 50. 
 
3.3 Sphere forming 
For the spheroid-forming assay, cells were plated at 5 cells/well in ultra-low-
attachment 96-well or in ultra-low-attachment 100 mm plates (Corning) in 
serum-free Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 Ham 
(DMEM/F12 = 1:1, Life Technologies), supplemented with 2% B27 and 
enriched for 10 ng/ml of EGF (epidermal growth factor) (Miltenyi Biotec) 
and 20 ng/ml of bFGF (basic fibroblast growth factor) (Miltenyi Biotec) 
growth factors. Cells were maintained in a humidified atmosphere of 5% 
CO2 at 37°C. Spheres were counted and their diameters measured after 15 
days.  
 
3.4 Self-renewal and limiting dilution assay 
 For in vitro serial passaging, thyrospheres were collected by gentle 
centrifugation at 800 rpm for 5 min and dissociated mechanically. The 
dissociated cells were passed through 40 µm mesh filters (BD Falcon Cell 
Strainer, Franklin Lakes, NJ) to eliminate doublets or triplets. Single cells 
were plated at 5 cells/well on ultra-low attachment 96-well plates to generate 
second and third generations for self-renewal of thyrospheres 50. 
The aim of Limiting Dilution Assay is to estimate the enrichment of stem 
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cells in a large population. This subpopulation represents the part of the cells 
that shows “active cell frequency”. For limiting dilution assay 72 cells were 
plated in decreasing numbers at 1, 5, 10, and 50 cells/well. Cultures were 
maintained until day 15, when the number of wells containing spheres for 
each cell plating density (number of positive cultures) was recorded, 
calculated and plotted using online ELDA analysis program 
(Http://bioinf.wehi.edu.au/software/elda). ELDA indicated significant 
differences in stem cell frequencies between the 8505c pBabe and 8505c 
OCT4/SOX2 cells 50. 
 
3.5 Migration assay  
Migration assay was performed in a 48-well-modified Boyden chamber 
(Neuroprobe). Briefly, 30 µl of complete DMEM medium were applied in 
the lower compartment the Boyden chamber. 10 µm-thick uncoated 
nucleopore membrane (Neuroprobe) with a pore diameter of 8 µm, 
previously treated with Fibronectin (50 µg/ml Sigma), was applied on 
Boyden chamber. 2×105/ml 8505c OCT4/SOX2 and TPC-1 OCT4/SOX2 
stable clones and relative controls were applied to the upper part of the 
membrane (106/ml). Cells were incubated for 8-10 hours at 37°C in 5% CO2 
atmosphere. The membrane were then carefully disassembled and fixed with 
methanol (100%). To check the migrated cells, we performed haematoxylin-
eosin staining. The average number of migrated cells from 15 representative 
fields (three replicates per condition) was counted under a phase contrast 
microscope 43.  
 
3.6 RNA, cDNA and Q-PCR 
Total RNA was isolated by the RNeasy Kit (Qiagen Hilden, Germany); the 
principle of this purification is the affinity chromatography during which 
RNA longer than 200 bases binds to the RNeasy silica membrane. Cells were 
harvested in lysis buffer RTL, supplemented with β-mercaptoethanol (10 µl 
per1 ml of lysis buffer). After the addition of ethanol 70%, the lysate was 
loaded on the column and centrifuged. Then, the washing buffer RW1 was 
added into the column which was centrifuged again and, consequently, it has 
been possible to carry out the treatment with DNase, dissolved in buffer 
RDD, to eliminate possible contaminations due to the presence of total 
genomic DNA. Other washes were performed with RW1 and RPE buffers; 
RNA, bound to the affinity column’s resin, was eluted by adding sterile H2O 
RNase free (DEPC water), to avoid degradation. cDNA synthesis was 
conducted as follows: random-primed first strand cDNAs were synthesized 
in a 50 µl reaction volume starting from 2 µg RNA using the GeneAmp RNA 
PCR Core Kit (Applied Biosystems, Warrington, UK). RNA was incubated 
with MgCl2, 10x buffer solution, Random Hexamers 73, RNase Inhibitor, 
dNTP (Deoxyribonucleotide triphosphate) and Reverse Transcriptase. To 
 19 
start the cDNA synthesis, the enzyme uses an RNA-complementary 
oligonucleotide; the synthesized single-strand DNA is then used as template 
for the synthesis of the second strand and then for the amplification with 
PCR. RNase (usually derived from the bacterium Escherichia coli) degrades 
the original RNA strand that has been used as a template by reverse 
transcriptase. Thus, the mechanism consists of repeated cycles of 
amplification: denaturation of DNA template, primers-annealing to the target 
sequence (which occurs at the annealing temperature dependent on their 
length and base-composition) and a final extension. 
Q-PCR allows measuring the levels of a gene expression after its cDNA 
amplification; a specific fluorescent dye, SYBR Green, which intercalates in 
the double-strand DNA, is used to quantify amplified cDNA and the increase 
in fluorescence is directly proportional to the amount of amplified sample 
present in the reaction. This method was performed by using the SYBR 
Green PCR Master mix (Applied Biosystems) in the iCycler apparatus (Bio-
Rad, Munich, Germany). Amplification reactions (25 µl final reaction 
volume) contained 200 nM of each primer, 3 mM MgCl2, 300 µM dNTPs, 1x 
SYBRGreen PCR buffer, 0.1U/ µl AmpliTaq Gold DNA Polymerase 
(Applied Biosystems), 0.01U/ µl Amp Erase (Applied Biosystems), RNase-
free water and 2 µl cDNA samples. Thermal cycling conditions were 
optimized for each primers pair. To verify the absence of non-specific 
products, 8 cycles of melting curve (55°C for 10 sec) were performed. As 
previously described, amplification is monitored by measuring the increase 
in fluoresce caused by the SYBR-Green binding to double-strand DNA and 
the amplification of GAPDH (Glyceraldehyde 3-phosphate dehydrogenase: 
housekeeping gene, constitutively expressed) was used for normalization. 
Fluorescent threshold values were measured in triplicate and fold changes 
were calculated by the formula 2-(sample 1 ΔCt - sample 2 ΔCt), where ΔCt 
is the difference between the amplification fluorescent thresholds of the 
mRNA of interest and the GAPDH mRNA. Primers were designed by using 
software available at:   
http://frodo.wi.mit.edu/cgibin/primer3/primer3_www.cgi and synthesized by 
Eurofins Genomics.  
The employed primer sequences are reported in the table below: 
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    Table 1 
 
Name  Forward 5’à  3’  Reverse5’à  3’ 
hGAPDH ctgccactgaaaaggaggag ttggcactccttgggttatc 
hSOX2  gcgaaccatctctgtggtct aaaatggaaagttgggatcg 
hOCT4 agcaaaacccggaggagt ccacatcggcctgtgtatatc 
hABCG2 tggatttacggctttgcagc tcctgttgcattgagtcctgg 
hNANOG  tacctcagcctccagcagat Ttgctattcttcggccagtt 
hALDH gcaactgaggaggagctctg Ttcgattaaatcagccaacttgt 
hNestin gaaacagccatagagggcaaa Tggtttccagagtcttcagtga 
hPD-1 cgcccttgtgctgatcctg Tgctggtagtggtacatctcc 
hPDL-1 agatgtgaaattgcaggatgcagg Caattccaagagagaggagaagct 
hPD-L2 atgatcttcctcctgctaat Tcagatagcactgttcacttccctc 
hIDO actgtgtcctggcaaactggaag Aagctgcgatttccaccaatagag 
hTGF-β tggcgttaccttggtaacc Ggtgttgagccctttccag 
 
3.7 Cytofluorimetric analysis  
Briefly, cells were incubated (30 min at 4°C) with specific or isotype control 
Abs. When necessary, we performed cell membrane permeabilization using 
the Cytofix/Cytoperm kit (BD Biosciences, Canada). Primary antibodies 
used were reported in the table below: 
 
             Table 2 
 
Description 
Anti human IDO efuor 660 eBioscienceTM 
Anti human CD279 (anti-PD-1) eBioscienceTM 
Anti human 274 biotin (anti PD-L1) eBioscienceTM 
Anti human SOX2 antibody  Abcam 
Anti human OCT4 antibody Abcam 
Anti human CD273 PE (anti PD-L2) Miltenyi Biotec 
Anti mouse CD45-PE Miltenyi Biotec 
Anti mouse CD8a-PerCP-Vio700 Miltenyi Biotec 
Anti mouse CD4-PerCP-Vio700 Miltenyi Biotec 
Anti mouse CD3e-PerCP-Vio700 Miltenyi Biotec 
 
Cells were analyzed with a FACS Calibur cytofluorimeter using Cell Quest 
software (BD Biosciences, Canada). A total of 104 events for each sample 
were acquired in all cytofluorimetric analyses. Thyroids from C57BL/6 and 
C57BL/6 TG-TRK mice were subjected to mechanical disaggregation 
(GentleMACS™ Dissociator by Miltenyi Biotec). Cells were centrifuged for 
5 min at 1200 rpm, resuspended in PBS  and then used for FACS analysis 43.	
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3.8 BrdU Incorporation 
Bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU) is a synthetic 
nucleoside analogue of thymidine. BrdU is used to detect proliferating cells. 
BrdU can be incorporated into the newly synthesized DNA of replicating 
cells (during the S phase of the cell cycle), substituting for thymidine during 
DNA replication. Cells were grown in 60 mm plates until 70% of confluence. 
After an overnight starvation, BrdU was added at a final concentration of 30 
µM and the cells were incubated for 30-60 min. After this, the BrdU was 
removed and cells were detached from the plates and permeabilized. The 
pellet was resuspended in 0.3 ml PBS, and incubated with anti-BrdU 
monoclonal antibody in the dark for 1h. At this point, cells were washed, 
incubated with fluorochrome-labeled secondary antibody, and analysed with 
FACS as above mentioned. 
 
3.9 Propidium Exclusion assay 
To evaluate cell viability, we used Propidium Exclusion assay. Propidium 
iodide is a non-permeant membrane dye that is generally excluded from 
viable cells. PI binds to double stranded DNA by intercalating between base 
pairs. PI is excited at 488 nm and emits at a maximum wavelength of 617 
nm. In order to evaluate cell viability, cells were plated on 60 mm plates, 
serum deprived for 12 hours, harvested (including dead floating cells in the 
medium) and aliquoted up to 1 x 106 cells/1000 µL into FACS tubes. Cell 
pellets were washed 2X in PBS and resuspended in 100 µL of Flow 
Cytometry Staining Buffer in 2µg/mL PI. Cells were gently mixed and 
incubated for 1 minute in the dark. To adjust flow cytometer settings for PI, 5 
- 10 µL of PI staining solution to a control tube of otherwise unstained cells 
was added. Determination of PI fluorescence (using the FL-2 channel) was 
performed with a FACS Calibur™ instrument. 
 
3.10 Luciferase assay 
To verify the activation of stemness in TC cells, we used the Stem Cell 
Reporter Array, a commercial array that allows to test the activation of Stem 
Cell-related signalling pathways by using luciferase assays in a 96-well cell 
culture plate.  Each Cignal Reporter Assay (OCT4, Nanog, KLF4, SOX2, 
Myc, Hedgehog, Notch, Wnt, Pax6, MEF2) consists of a mixture of a 
pathway-focused transcription factor-responsive firefly luciferase construct 
and a constitutively expressing Renilla luciferase construct. 1x104 cells/well 
were added together with retrotrasfection reagent and then treated or not with 
IL-8. After 24 hours of treatment, luciferase activity was measured. To 
quantify luminescence, we used a dual-luciferase assay (Promega). 
According to standard protocol for Dual-Glo® Stop & Glo®, cells were 
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removed from the incubator and Renilla and Firefly luminescence was 
measured.  
 
3.11 Purification and vitality determination of peripheral 
blood lymphocytes  
Lymphocytes were purified from the peripheral blood of healthy volunteers, 
negative for HIV-1, HIV-2, hepatitis C virus, and hepatitis B virus Abs. 
Buffy coat cell packs were provided by the Immunohematology Service 
(University of Naples Federico II). Informed consent, according to the 
guidelines of University of Naples Federico II institutional review board for 
the use of human in research, was obtained. Cells were reconstituted in PBS 
containing 0.5 g/L HAS and 3.42 g/L sodium citrate and were layered onto 
histopaque1077 (Sigma Aldrich) and mononuclear cells were collected at the 
interface. Lymphocytes were further purified to wear homogeneity (95% - 
98%) by depleting monocytes using CD14 microbeads (Miltenyi biotec). The 
magnetically labeled by retaining them on a MACS column in the magnetic 
field of the MidiMACS (Miltenyi biotec). 
 
 3.12 Xenografts in Mice 
To evaluate cell tumorigenic potential, xenograft experiments were 
conducted. 1x106 8505c parental or OCT4/SOX2 cells were injected into 
dorsal portion of 4-week-old mice (10 CD1 nu/nu mice per group). Tumour 
diameters were measured at regular intervals with a caliper. Tumor volumes  
were calculated with the formula: V=(A*B2)/2 (A=axial diameter; 
B=rotational diameter). This study was conducted in accordance with Italian 
regulations for experimentation on animals.  
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4.Results 
 
4. 1 IL-8 stimulation induces stemness in TC cell lines  
To identify stemness-related gene induction upon IL-8 treatment, we used a 
stem cell reporter assay, which allows to define the activity of several 
promoter of genes linked to stemness in response to different stimuli. To this 
aim, 8505c cells, derived from human ATC, were selected. These cells 
express the BRAFV600E mutant protein. Reverse transfection was performed 
into a multiwell plate containing the luciferase reporter gene under the 
transcriptional control of a basal promoter element joined to tandem repeats 
of specific stemness-related transcriptional response elements (Figure 4). 
Upon transfection, 8505c cells were incubated for 48h in the presence of the 
indicated plasmids. In the last 24 hours, cells were stimulated with IL-8 (100 
ng/ml) or left untreated. At the end of the experiments, luciferase activity 
was detected by luminescence measurements, as described in materials and 
methods. As shown in Figure 4, IL-8 was able to significantly induce the 
activation of various promoters, including OCT4, NANOG, KLF4, SOX2, 
MYC, HEDGEHOG, WNT, and , to a lesser extent, of MEF2, PAX6 and 
NOTCH. These results indicate that IL-8 is able to induce and sustain 
stemness of TC cells, and confirmed our previous observation that OCT4 and 
SOX2 could be induced  upon IL-8 treatment.  
 
Figure 4: 8505c cells, derived from an human anaplastic thyroid carcinoma (ATC), were 
used for reverse transfection in a multiwell plate containing the indicated reporter vectors, 
and promoter activity was evaluated both in the presence and in the absence of IL-8 
treatment (100 ng/ml for 24 h). Promoter activity of not-treated cells is represented by the 
dotted line.  Mean ± SEM of three experiments. *, p<0.05 compared to the relative not-
treated control. 
 
 
 24 
4.1.1 Generation and functional characterization of 
OCT4/SOX2 overexpressing TC cells 
We had shown that IL-8 treatment enhanced OCT4 and SOX2 gene 
expression in TC cells 43 50. Furthemore OCT4 and SOX2 resulted strongly 
enriched in TC SCs 43 50. Moreover, IL-8 treatment caused the activation of 
OCT4/SOX2-dependent promoters (Figure 4). Thus, OCT4 and SOX2 
represent also in TC cells critical mediators of stemness. In order to obtain a 
stem-like population to study properties and functions of TC SCs, and to 
define the role of OCT4 and SOX2 in TC, we generated TC cells (8505c and 
TPC-1) overexpressing the two transcriptional factors.  TPC-1 cells derive 
from a human PTC carrying a RET/PTC1 rearrangement. 
 
  
 
Figure 5: mRNA fold increase of OCT4 and SOX2 in 8505c or TPC-1 cells transfected with 
both OCT4 and SOX2 expressing vectors compared to the expression levels of empty vector 
(pBABE) transfected cells (dotted line). Mean ± SEM of three independent evaluations. *, 
p<0.05 compared to empty vector transfected cells. 
 
To this aim, 8505c and TPC-1 cells were transfected with OCT4 and SOX2 
expression vectors. Transfected cells were subjected to puromycin selection. 
As a control, we also generated parental cells expressing empty vector 
(pBABE).  Antibiotic-resistant clones were collected, expanded and 
successively analysed for OCT4 and SOX2 expression levels by quantitative 
PCR and cytofluorimetric analysis. As shown in Figure 5, two clones co-
expressing ectopic OCT4 and SOX2 were selected for each cell line for 
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further experiments. OCT4 and SOX2 protein expression levels were 
evaluated by FACS analysis in the same clones (Figure 6). Thus, we 
obtained 8505c and TPC-1 cells featuring ectopic expression of both the 
OCT4 and SOX2 transcriptional factors.   
 
 
 
Figure 6: Mean Fluorescence Intensity evaluated by FACS analysis of OCT4 and SOX2 in 
8505c or TPC-1 cells transfected with both OCT4 and SOX2 expressing vectors compared to 
the expression levels of empty vector transfected cells (dotted line). Mean ± SEM of three 
independent evaluations.*, p<0.05 compared to empty vector transfected cells. 
 
The selected TPC-1 OCT4/SOX2 and 8505c OCT4/SOX2 cells were 
characterized for their growth and viability features. To this aim, we first 
evaluated the growth rate of these cells by performing growth curves in 
complete medium (DMEM - 10% FBS). These experiments showed that the 
growth capacity of both 8505c and TPC-1 OCT4/SOX2 clones was 
significantly higher than that of control cells (Figure 7). In line with these 
results, OCT4/SOX2-overexpressing 8505c or TPC-1 cells displayed a 
significant increase in DNA synthesis rate, as assessed by BrdU 
incorporation assay (Figure 8). In order to evaluate cell viability/apoptosis 
under stress conditions, we used Propidium Iodide 3 exclusion assay. Cells 
were plated, serum deprived for 24 hours, and then stained with PI. Figure 9 
shows representative FACS analyses demonstrating that OCT4/SOX2 
overexpressing clones displayed increased cell death compared to control 
cells upon serum starvation.  
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Figure 7: Growth curves in 10% FBS of 8505c or TPC-1 transfected with the empty vector 
(pBABE) and of two clones overexpressing OCT4 and SOX2. Mean ± SEM of triplicate 
determinations. *, p<0.05 compared to empty vector transfected cells. 
 
 
 
 
Figure 8: BrdU Incorporation evaluated by FACS analysis of 8505c or TPC-1 transfected 
with the empty vector (pBABE) and of two clones overexpressing OCT4 and SOX2. A 
representative experiment is shown. *, p<0.05 compared to empty vector transfected cells. 
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Figure 9: Percentage of dead cells assessed by FACS analysis through Propidium Iodide 3 
staining of 8505c or TPC-1 transfected with the empty vector (pBABE) and of two clones 
overexpressing OCT4 and SOX2. A representative experiment is shown.*, p<0.05 compared 
to empty vector transfected cells. 
 
These apparently contrasting results could be explained with the observation 
that some of the genes activated during reprogramming can cause detrimental 
effects including apoptosis and/or senescence 74. It has been in fact 
demonstrated that the pro-apoptotic factor BAX is upregulated in response to 
the expression of OCT4, SOX2 and KLF4, and that the expression of the 
antiapoptotic BAX-antagonist molecule BCL2 results in enhanced 
reprogramming efficiency of iPSCs (induced Pluripotent Stem Cells) 75.  
We then asked whether OCT4 and SOX2 overexpression could cause a more 
aggressive phenotype of TC cells. To this aim, we evaluated their capacity to 
migrate. Both 8505c and TPC-1 OCT4/SOX2 cells showed a significant 
increase in their migratory potential compared to control cells (Figure 10). 
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Figure 10: Number of migrated cells evaluated using a Boyden Chamber.  8505c or TPC-1 
transfected with the empty vector (pBABE) and two clones overexpressing OCT4 and SOX2 
were used. Mean ± SEM of three experiments.*, p<0.05 compared to empty vector 
transfected cells.  
 
In conclusion, the enforced expression of OCT4/SOX2 in both PTC and 
ATC cell lines cells triggers a complex phenotype, characterized by 
enhanced DNA synthesis and proliferation, increased apoptotic rate in stress 
conditions, and enhanced migratory potential. 
 
4.1.2 Stemness features of OCT4/SOX2 expressing TC cells  
To define the stemness potential of OCT4/SOX2 overexpressing TC cells, 
we used different assays. In general, stemness features can be evaluated in 
cultured cells by checking the levels of stemness-related mRNAs and 
proteins, by evaluating the ability to grow in low-adherence conditions 
(sphere-forming, limiting dilution and self-renewal assays), and by 
measuring tumorigenic activity.  Thus, we first evaluated the expression 
levels of mRNAs encoding for various stemness markers (NANOG, ABCG2, 
ALDH and NESTIN) by real-time PCR in TPC-1 OCT4/ SOX2, 8505c 
OCT4/SOX2 and in the respective control cells grown in adherence. As 
shown in Figure 11A, OCT4/SOX2 TC cells display a statistically 
significant increase in the mRNAs for stemness markers compared to control 
cells.  Moreover, we investigated the hypothesis that OCT4/SOX2 
overexpression can modulate the mRNA expression of EMT markers. Using 
real-time PCR we demonstrated that the expression level of three different 
EMT markers (SNAIL, SLUG and ZEB1) significantly increases compared 
to control cells (Figure 11B). 
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Figure 11A: mRNA fold increase of stemness markers (Nanog, ABCG2, ALDH, Nestin) in 
8505c OCT4/SOX2 or TPC-1 cells OCT4/SOX2 compared to the expression levels of empty 
vector-transfected cells (dotted line). Mean ± SEM of three independent evaluations. *, 
p<0.05 compared to empty vector transfected cells.  
11B: mRNA fold increase of EMT markers (SLUG, SNAIL, and ZEB1) in 8505c 
OCT4/SOX2 or TPC-1 cells OCT4/SOX2 compared to the expression levels of empty 
vector-transfected cells (dotted line). Mean ± SEM of three independent evaluations.*, 
p<0.05 compared to empty vector transfected cells.  
One of the more popular methods to isolate and characterize CSCs and to 
assess their stemness potential in vitro is based on the capacity of these cells 
to grow in low-adherent conditions is the sphere formation assay.  The 
inhibition of adhesion, in fact, induces cell death through anoikis in 
nonmalignant and differentiated epithelial cells. On the other hand, under the 
same culture conditions, undifferentiated/stem-like tumour cells proliferate 
and grow as floating clusters termed tumorspheres. Tumorsphere-forming 
efficiency generally correlates with stemness features 76. By using this assay, 
we observed that OCT4/SOX2 cells displayed, compared to controls, an 
increased sphere-forming efficiency, as assessed by both sphere number and 
diameter (Figure 12). Another classical feature of CSC is the ability to self-
renew. Self-renewal ability can be evaluated both in vivo and in vitro. To 
evaluate self-renewal in vivo, putative CSCs are xenotransplanted into 
immunodeficient mice to allow tumour formation, and long-term tumour-
propagating capacity is measured. To evaluate self-renewal in vitro, 
tumourspheres are serially passaged for few generations, and sphere-forming 
efficiency is measured at each generation. 
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Figure 12: Sphere-forming efficiency, assessed as both sphere number  and diameter (left), 
of 8505c or TPC-1 transfected with the empty vector (pBABE) and of two clones 
overexpressing OCT4 and SOX2. Mean ± SEM of three experiments. *, p<0.05 compared to 
empty vector transfected cells.  
 
In synthesis, self-renewal measures the ratio of symmetrical/asymmetrical 
cell divisions. Thus, in order to evaluate whether OCT4 and SOX2 can 
increase the self-renewal ability of TC cells, we performed a sphere-forming 
assay across generations. Figure 13 shows that 8505c empty vector-
transfected cells (pBABE) are able to form spheres until second generation 
(F2) albeit with reduced efficiency with respect to F1. On the contrary, two 
OCT4/SOX2 overexpressing clones formed spheres until third generation.  
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Figure 13: Self-renewal efficiency of 8505c cells transfected with the empty vector 
(pBABE) and of two clones overexpressing OCT4 and SOX2. *, p<0.05 compared to empty 
vector transfected cells.  
 
Moreover, the sphere-forming efficiency of OCT4/SOX2 clones was 
significantly higher than that of parental cells at F1 and F2 generations. 
To assess the role of OCT4 and SOX2 on the clonogenic capacity of TC SCs, 
we performed a limiting dilution assay on 8505c pBabe and on 8505c 
OCT4/SOX2 cells. We demonstrated that these two stemness factors 
significantly increased the clonogenic potential of 8505c (Figure 14). 
Collectively, these results confirmed that OCT4 and SOX2 transcriptional 
factors represent key regulators in the induction and promotion of TC cell 
stemness. 
 
 
 
Figure 14: Extreme limiting dilution assay of 8505c cells transfected with the empty vector 
(pBABE) and of two clones overexpressing OCT4 and SOX2. The graph presents the 
clonogenic potential of each cell line. Mean ± SEM of three experiments. *, p<0.05 
compared to empty vector transfected cells.  
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One of the features of CSCs is the ability to initiate tumours in xenograft 
experiments. Thus, to evaluate the tumourigenic activity of 8505c pBABE 
and 8505c OCT4/SOX2 cells, we performed xenotransplantation 
experiments. To this aim, two groups of 10 mice (CD1 Nu/Nu, females), 
were subcutaneously injected with 1x106 cells, and tumour growth was 
measured weekly. 1x106 cells represent for 8505c pBabe cells the limiting 
number whit which tumour formation can be detected. We found that 
OCT4/SOX2 overexpressing clones displayed higher tumorigenic potential 
with respect to the control 8505c cells. In fact, while the 8505c OCT4/SOX2 
cells xenotransplanted into nude mice exhibited a tumour incidence of 50%, 
the 8505c pBABE tumour-forming efficiency was 16.6%. In addition, the 
tumours formed by 8505c OCT4/SOX2 clones were larger than those formed 
by control cells at the end of the experiments (Table 3). 
 
 
 
 
Table 3: Tumor incidence (%) and tumor volume (cm3) of 8505c pBABE and of 8505c 
OCT4/SOX2 cl16 cell xenografts. *, p<0.05 compared to empty vector transfected cells.  
 
4.2 Imunosuppressive phenotype of OCT4/SOX2-expressing 
TC cells 
It is well known that CSCs are considered responsible of the aggressiveness 
of many types of tumours. One of the possible reason of such behaviour 
might be the ability of CSCs to evade the anti-cancer immune surveillance. 
To verify whether this is also the case for TC cells, we correlated stemnness 
features of TC cells with their immunosuppressive properties. To this aim, 
we evaluated the expression levels of various immunomodulatory molecules 
in TC cell lines overexpressing or not OCT4/SOX2 by real-time RT-PCR 
and FACS analyses. These experiments demonstrated that, among various 
immunosuppressive molecules, IDO, PD-L1, PD-L2 and TGF-β were 
enriched in OCT4/SOX2 8505c and OCT4/SOX2 TPC-1 cells compared to 
controls (Figure 15).  
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Figure 15: mRNA fold increase of the indicated immunomodulatory markers in 8505c 
OCT4/SOX2 or TPC-1 OCT4/SOX2 cells compared to empty vector transfected cells 
(dotted line). Mean ± SEM of three independent evaluations.*, p<0.05 compared to empty 
vector transfected cells. 
 
Furthermore, we analysed the mRNA expression of the immune checkpoints 
PD-L1 and PD-L2, and of IDO in pBABE cells or in cells overexpressing 
OCT4/SOX2 grown in adherence and as thyrospheres. As shown in Figure 
16, the expression levels of PD-L2 and IDO significantly increased in 
thyrospheres of 8505c pBABE cells compared to the same cells grown in 
adherence (dotted line). The expression of PD-L1 and IDO resulted 
significantly increased in 8505c OCT4/SOX2 thyrospheres in comparison to 
the same cells grown in adherence. 
 
 
 
Figure 16: mRNA fold increase of IDO, PD-L1, and PD-L2 in 8505c pBABE thyrospheres, 
OCT4/SOX2 adherent or OCT4/SOX2 cl16 thyrospheres compared to the expression levels 
of 8505c pBABE cells grown in adherence (dotted line). Mean ± SEM of three independent 
evaluations. *, p<0.05 compared to 8505c pBABE adherent cells. 
 34 
 
To confirm the above mentioned results also at the protein level we analysed 
the expression of PD-L1 and PD-L2 and of their receptor PD-1 in 8505c cells 
overexpressing or not OCT4/SOX2 by FACS analysis. We found that PD-L1 
and PD-L2 protein levels increase in cells overexpressing OCT4 and SOX2 
transcriptional factors (Figure 17A, 17B) with respect to control cells. 
Interestingly, TC cells displayed a detectable level also of the receptor PD-1. 
A further increase in its expression levels in particular in 8505c OCT4/SOX2 
expressing cells was observed (Figure 17). These observations support the 
hypothesis that stemness increases immunosuppressive features of TC cells. 
Since IL-8 increases stemness in a SLUG-dependent fashion, we verified, by 
similar approaches, whether PD-1, PD-L1 and PD-L2 expression could be 
regulated by IL-8 treatment. TC cells overexpressing the transcriptional 
factor SLUG or IL-8, that display increased stemness features, expressed 
higher levels of immunomodulatory molecules compared to control cells. 
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Figure 17: A) PD-1, PD-L1, and PD-L2 expression levels in 8505c or TPC-1 pBABE or one 
representative OCT4/SOX2 overexpressing clone B): PD-1, PD-L1, and PD-L2 expression 
levels in 8505c or TPC-1 pBABE or OCT4/SOX2 overexpressing clones. Mean ± SEM of 
three experiments.  *, p<0.05 compared to pBABE cells. 
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Figure 18: A) PD-1, PD-L1, and PD-L2 expression levels in 8505c parental cells treated or 
not with IL-8(100 ng/ml) for 24h. A representative experiment is shown B) PD-1, PD-L1, 
and PD-L2 expression levels in 8505c treated or not with IL-8 (100 ng/ml). Mean ± SEM of 
three experiments. *, p<0.05 compared to not-treated  cells. C) PD-1, PD-L1, and PD-L2 
expression levels in 8505c controls, overexpressing SLUG, or SLUG silenced (shSLUG) 
cells. Mean ± SEM of three clones. *, p<0.05 compared to controls. 
 
By using both real-time PCR and FACS analyses we could confirm that IL-8 
treatment causes an up-regulation of mRNA and protein levels of the 
immunomodulatory molecules (Figure 18A, 18B). Consistently, 8505c 
SLUG cells, that exhibit increased EMT and stemness features 43, also 
featured increased PD-1 and PD-L1 protein levels compared to control cells. 
On the contrary, in 8505c cells silenced for SLUG, we observed a significant 
reduction of PD-L1 and PD-L2 protein levels with respect to control cells 
(Figure 18C).  
We also characterized in 8505c OCT4/SOX2 or 8505c SLUG cells the 
expression levels of IDO. We demonstrated that IDO protein levels and the 
percentage of IDO-positive cells increase in both 8505c and TPC-1 cell lines 
overexpressing OCT4/SOX2 compared to control cells (Figure 19A). 
Consistently, SLUG overexpression in 8505c increased the expression of 
IDO, whereas its silencing was associated to a decrease in the expression of 
the IDO protein (Figure 19B). 
Taken together, these results suggest that stemness induction, either caused 
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by EMT-through IL-8 stimulation or SLUG enforced expression, or by direct 
OCT4/SOX2 enforced expression, correlates with the acquisition of an 
immunosuppressive phenotype of TC cells. 
 
 
  
 
Figure 19: A) IDO expression levels and percentage of IDO positive cells in 8505c or TPC-
1 transfected with the empty vector (pBABE) and in two clones overexpressing OCT4 and 
SOX2. Mean ± SEM of three clones.  *, p<0.05 compared to empty vector transfected cells. 
19B) IDO expression levels and percentage of IDO positive cells in 8505c control, 
overexpressing SLUG, or SLUG silenced (shSLUG) cells. Mean ± SEM of three clones. *, 
p<0.05 compared to control cells.  
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To assess the expression of the immunomodulatory molecules in a panel of 
TC cells, we checked their expression levels in several PTC-derived (BcPAP, 
TPC-1) or ATC-derived (8505c, Cal62, SW1736, FRO, BHT101) cell lines 
compared to normal immortalized thyroid epithelial cells (Nthy-ori) (Figure 
20). We found that the level of expression of both PD-L1 and IDO, but not 
PD-L2 (data not show), tend to increase in TC cell lines compared to control 
cells and it was in mean higher in ATC-derived compared to PTC-derived 
cell lines (Figure 21). Thus, immunosuppressive phenotype correlates with 
aggressiveness in TC cell lines. 
 
 
 
 
 
Figure 20: A) protein expression levels assessed by FACS analysis of PD-L1 and IDO in 2 
PTC-derived and 5 ATC-derived cell lines compared the expression levels detected in Nthy-
ori normal immortalized thyroid cells. Mean ± SEM of three determinations. p<0.05 
compared to NThy cells  B) Mean of ATC-derived compared to PTC-derived cell lines.  
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4.2.1 Functional role of immune checkpoints in TC 
We then asked whether the up-regulation of the immunomodulatory 
molecules induced by OCT4 and SOX2 could sustain functional 
immunosuppression of T lymphocytes. To this aim, peripheral blood 
lymphocytes were isolated from different donors and tested for vitality both 
in the presence of TC cell-derived conditioned media (TC CM) or in a co-
culture system with TC cell lines. We observed that TC cells overexpressing 
OCT4 and SOX2, when co-cultured with lymphoid cells, caused a significant 
reduction of lymphocyte vitality compared to control cells. These effects 
were not observed when lymphocytes were stimulated with conditioned 
media derived from the same cells (data not shown). Thus, OCT4 and SOX2 
can increase the immunosuppressive functions of TC cells, possibly by the 
engagement of cell-cell contact mechanisms (i.e. PD-L1 and/or PD-L2) and 
not by the release of soluble factors. 
 
 
  
Figure 21: A) Percentage of vital T lymphocytes isolated from 3 different donors after 24 h 
of co-culture with 8505c or TPC-1 transfected with the empty vector (pBABE) or with two 
clones overexpressing OCT4 and SOX2. *, p<0.05 compared to empty vector transfected 
cells. B) Percentage of vital T lymphocytes isolated from 3 different donors after 24 h of co-
culture with 8505c transfected with the empty vector (pBABE) and with an IL-8 or SLUG 
vector. The mean of three clones is shown. *, p<0.05 compared to empty vector transfected 
cells. 
 
We then evaluated the expression levels of immunosuppressive factors in a 
model of TC in mice. To this aim, we used C57BL/6 mice expressing the 
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TRK-T1 oncogene under the control of the thyroid specific TG promoter 43. 
TRK-T1 oncogene promotes the spontaneous development of tumours or 
hyperplastic lesions at 1 year (data not shown). At the same time point, we 
collected thyroids from both wild-type and transgenic mice, and analysed 
them for the expression of PD-1, PD-L1 and PD-L2 by Real-time PCR. We 
found a strong increase in the expression of PD-L1 in the pathological 
thyroids derived from the TRK-T1 mice with respect to the control thyroids 
(Figure 22A). No increase in PD-1 or PD-L2 expression was observed. In 
line with this observation, the number of CD8+ T lymphocytes infiltrating 
mouse thyroids was strongly reduced in TRK-T1 mice with respect to control 
(Figure 22B). These data indicate that, similarly to what observed in other 
cancer types, also in thyroid carcinomas tumour progression is accompanied 
by the acquisition of immunosuppressive features. 
 
 
 
Figure 22: A) mRNA expression of PD-1 and PD-L1 in the thyroid tissues obtained from 3 
control mice (C57BL/6) or 3 mice expressing TRK-T1 oncogene under the control of thyroid 
specific thyreoglobulin (TG) promoter. B) Percentage of CD8+ T lymphocytes infiltrating 
mouse thyroids, as assessed by FACS analysis of the dissociated tissues obtained from 3 
control mice (C57BL/6) or 3 mice expressing TRK-T1 oncogene, developing thyroid 
tumours. *, p<0.05 compared to controls  
 41 
5. Conclusion/ Discussion 
 
Thyroid cancer (TC) is the most common endocrine malignancy and its 
incidence is increasing. Despite well-differentiated forms, including papillary 
thyroid carcinomas (PTCs), follicular thyroid carcinomas (FTCs), have an 
excellent prognosis, with more than 90% cured by therapy, a small 
percentage (approx. 5%) of tumours becomes resistant to radioiodine therapy 
(radioactive iodine resistant-RAIR), the main treatment for these patients. 
Poorly differentiated thyroid carcinomas (PDTC), that invariably evolve in 
RAIR tumours, and anaplastic thyroid carcinomas (ATC), which are by 
definition RAIR, show limited options of treatment. 
The scientific community believes that a small population of cells (cancer 
stem-like cells, CSCs) within the tumour is responsible for resistance to 
chemo-radiotherapy, recurrence and metastasis. Various studies supported 
this concept, thus strengthening the importance to characterize CSC 
populations in each cancer type. ATC, besides being the most aggressive 
among all thyroid cancers, and one of the most aggressive among all human 
cancer types, display stem-like features. ATCs features high levels of 
stemness markers and a stem-like behaviour. Recently, a CSC population has 
been identified in human ATCs samples, based upon the ability of this 
subpopulation to express high aldehyde dehydrogenase activity, to form 
thyrospheres in low adherence conditions and to form tumours in serial 
transplantation experiments. ATCs CSCs are more abundant and more 
aggressive than the CSC population found in PTCs 30. In TC, stemness 
features correlate with the acquisition of Epithelial-to-Mesenchymal 
Transition (EMT) 78. 
We have previously shown that the pro-inflammatory cytokine IL-8 induces 
stemness features in TC, through the induction of EMT 43. We also found 
that IL-8 induces stemness properties in TC through the up-regulation of the 
SLUG EMT transcriptional factor 43. Consistently, we found that IL-8 
stimulation of TC cells induces the expression of stemness-related genes, 
including OCT4, SOX2, and NANOG. SOX2 and OCT4 stand at the top of a 
hierarchy governing the regulation of self-renewal, pluripotency and de-
differentiation 79. The roles of OCT4 and SOX2 have been described in 
various tumours 80.  
Here, we generated OCT4 and SOX2-overexpressing PTC and ATC cell line 
models to characterize the effects of the two transcriptional factors in TC, 
and to obtain TC cells with enhanced stemness features, with which to study 
the features of TC stem-like cells. OCT4/ SOX2 TC cells show an increase in 
the proliferation rate and also in the death rate. These apparently contrasting 
results suggest that some of the genes activated in response to OCT4 and 
SOX2 may be responsible for an antiproliferative response such as apoptosis, 
senescence or other forms of cell-cycle arrest 74. This phenomenon has been 
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defined as “reprogramming-induced senescence” 74. Our data also support 
the finding that reprogramming factors can trigger apoptosis. It has been 
demonstrated for example that BAX is upregulated in response to the 
expression of OCT4, SOX2 and KLF4, and that the co-expression of the 
BAX antagonist BCL2 results in enhanced reprogramming efficiency 75.  It is 
possible that also in TC cells, the expression of the reprogramming factors 
OCT4 and SOX2 induces cell death by increasing the amount of pro-
apoptotic proteins. We are currently analysing this possibility. 
In both ATC (8505c) and PTC (TPC-1) cells, enforced expression of 
OCT4/SOX2 caused an increase in cell motility, as assessed by migration 
assays. Moreover, OCT4/SOX2 induced an enhancement of stemness 
features, including self-renewal and tumorigenic potential, as assessed by 
self-renewal and limiting dilution assays and tumorigenicity experiments in 
immunodeficient mice.  
There is increasing evidence that CSCs are responsible for the aggressive 
behaviour of tumours. This is not only due to CSC resistance to anti-cancer 
therapy and increased metastatic activity, but also to the ability of CSCs to 
evade the immune system.  CSCs possess features similar to normal stem 
cells in their ability of inducing immune modulation. Unfortunately, 
possession of these features by CSCs contributes to their escape from the 
immune system recognition.  
Here, we demonstrated that stemness is closely linked with 
immunosuppressive phenotype in TC cells. In fact, TC cells with increasing 
aggressive features also display increased immunsoppressive functions. The 
immunosuppressive phenotype of TC cells is characterized by increased 
expression of PD-L1, PD-L2, IDO, observed in PTCs versus normal thyroid 
cells, and in ATCs versus PTCs. Moreover, OCT4/SOX2 overexpressing TC 
cells display increased immunosuppressive features in comparison to 
parental cells. Not only were immunosuppressive molecules increased in 
OCT4/SOX2 TC cells, but also immunosuppressive activity on lymphocytes 
was enhanced. In fact, lymphocyte vitality was significantly reduced when 
co-cultured with OCT4/SOX2 TC cells when compared to control cells. This 
effect was not observed when lymphocytes were treated with conditioned 
media form TC cultures, but only when lymphocytes were co-cultured with 
TC cells. These observations indicate that OCT4 and SOX2 can increase the 
immunomodulatory functions of TC cells, possibly by the engagement of 
cell-cell contact mechanisms (i.e. PD-L1 and/or PD-L2). In support of these 
findings, we analysed the behaviour of immunosuppressive molecules in a 
mouse model of TC, in which the TRK-T1 oncogene is placed under the 
transcriptional control of the thyroid-specific TG gene promoter, thus 
causing the occurrence of thyroid hyperplasia and thyroid tumours. By 
comparing the immunosuppressive features of normal and pathological 
thyroids of these mice, we found an increase of the expression of PD-L1 in 
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the thyroids derived from the TRK-T1 mice with respect the control thyroids. 
Importantly, the increase in PD-L1 correlated with a decrease of CD8+ T 
lymphocytes infiltrating TG TRK-T1 thyroids. Therefore, TC display 
immunosuppressive features, and these features correlate with TC 
aggressiveness; moreover stemness features could enhance 
immunosuppressive ability of TC.  
A limited number of reports indicate that the immunomodulatory properties 
of CSCs derived from several tissues could be linked specifically to SOX2 
and/or OCT4 expression. Zhong et al. found that both SOX2 and PD-L1 
were expressed at a markedly higher level in hepatocellular carcinoma 
(HCC) tissues in comparison to adjacent non-tumour tissues 81. Moreover, 
the expression levels of both genes were correlated with each other. 
Knockdown of SOX2 reduced the cell proliferation ability and induced 
apoptosis of HCC cells 81. Noteworthy, the depletion of SOX2 also reduced 
the expression of PD-L1. Further analysis showed that there is a consensus 
SOX2 binding site in the promoter region of PD-L1. It has been also 
demonstrated that SOX2 directly bound to the PD-L1 promoter through the 
consensus SOX2 motif 81. Further evidence by luciferase reporter assays 
revealed that SOX2 promoted the transcription activity of PD-L1 promoter 
region through the SOX2 motif. Collectively, these data provide a novel 
insight into the function and the interplay of SOX2 and PD-L1 in HCC.  
Moreover, there are also evidence that PD-L1 can regulate stemness. In fact, 
specific knockdown of PD-L1 using shRNA revealed its critical role in the 
expression of OCT4 and NANOG in breast CSCs 82. Conversely, these 
factors could be induced upon PD-L1 ectopic expression in cells that are 
normally PD-L1 negative. Most importantly, down-regulation of PD-L1 
compromised the self-renewal capability of breast CSCs in vitro and in vivo 
as shown by tumoursphere formation assay and extreme limiting dilution 
assay, respectively. This study demonstrates a novel role for PD-L1 in 
identifying and sustaining CSCs of breast 82. 
There is growing interest toward therapies that target the CSC population 
within tumours. Moreover, immunotherapies directed against the PD-1/PD-
L1/PD-L2 circuit raised great expectations in the cure of various cancer types 
given the successful results obtained in the first clinical trials. Our data 
indicate that targeting stemness pathways in TC might not only inhibit its 
malignant features, but also limit its immunosuppressive capacity.  
  
 44 
 
LIST OF PUBLICATIONS 
 
Liotti F, Collina F, Pone E, La Sala L, Franco R, Prevete N, Melillo RM.  
“Interleukin-8, but not the Related Chemokine CXCL1, Sustains an Autocrine 
Circuit Necessary for the Properties and Functions of Thyroid Cancer Stem 
Cells” 
  Stem Cells. 2016 Aug 31. [Epub ahead of print]. Online ISSN: 1549-4918  
  
  
 45 
ACKNOWLEDGMENTS  
 
I carried out my study in the Molecular Medicine and Medical Biotechnology 
Department of Federico II University of Naples. 
Foremost, I would like to express my sincere gratitude to my tutor Prof. Rosa 
Marina Melillo for the continuous support of my PhD study and research, for 
her patience, and immense knowledge. Her guidance helped me in all the 
time of research and writing of this thesis. I want to thank Dott. Liotti 
Federica and Dott. Prevete Nella for their active participation and support in 
my PhD project for helping me in the experiments and stimulated discussion. 
I also want to thank all people that I meet during my PhD experience. 
I also want to thank Francesco for his love. 
Last but not the least my gratitude goes to my family for their encouragement 
and faith in me. 
 
 
 
 
 
 
 
 
 
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 46 
BIBLIOGRAFY 
 
1. Pellegriti G, Mannarino C, Russo M, et al. Increased mortality in 
patients with differentiated thyroid cancer associated with Graves' 
disease. The Journal of clinical endocrinology and metabolism. Mar 
2013;98(3):1014-1021. 
2. Wreesmann VB, Ghossein RA, Patel SG, et al. Genome-wide 
appraisal of thyroid cancer progression. The American journal of 
pathology. Nov 2002;161(5):1549-1556. 
3. Ciampi R, Knauf JA, Rabes HM, Fagin JA, Nikiforov YE. BRAF 
kinase activation via chromosomal rearrangement in radiation-
induced and sporadic thyroid cancer. Cell cycle. Apr 2005;4(4):547-
548. 
4. Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current 
diagnosis and treatment. Annals of oncology : official journal of the 
European Society for Medical Oncology. Sep 2000;11(9):1083-1089. 
5. Heikkila A, Siironen P, Hagstrom J, et al. Follicular thyroid 
neoplasm: clinicopathologic features suggesting malignancy. APMIS 
: acta pathologica, microbiologica, et immunologica Scandinavica. 
Nov 2010;118(11):846-854. 
6. Tanaka K, Sonoo H, Saito W, et al. Analysis of clinical outcome of 
patients with poorly differentiated thyroid carcinoma. ISRN 
endocrinology. 2011;2011:308029. 
7. Decaussin M, Bernard MH, Adeleine P, et al. Thyroid carcinomas 
with distant metastases: a review of 111 cases with emphasis on the 
prognostic significance of an insular component. The American 
journal of surgical pathology. Aug 2002;26(8):1007-1015. 
8. Volante M, Landolfi S, Chiusa L, et al. Poorly differentiated 
carcinomas of the thyroid with trabecular, insular, and solid patterns: 
a clinicopathologic study of 183 patients. Cancer. Mar 01 
2004;100(5):950-957. 
9. Nishida T, Katayama S, Tsujimoto M, Nakamura J, Matsuda H. 
Clinicopathological significance of poorly differentiated thyroid 
carcinoma. The American journal of surgical pathology. Feb 
1999;23(2):205-211. 
10. Pacini F, Castagna MG, Brilli L, Pentheroudakis G, Group EGW. 
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, 
treatment and follow-up. Annals of oncology : official journal of the 
European Society for Medical Oncology. Oct 2012;23 Suppl 
7:vii110-119. 
11. Pfister DG, Fagin JA. Refractory thyroid cancer: a paradigm shift in 
treatment is not far off. Journal of clinical oncology : official journal 
 47 
of the American Society of Clinical Oncology. Oct 10 
2008;26(29):4701-4704. 
12. Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic 
hallmarks of poorly differentiated and anaplastic thyroid cancers. The 
Journal of clinical investigation. Mar 01 2016;126(3):1052-1066. 
13. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and 
outcome of patients with papillary thyroid carcinoma: a 15-year 
median follow-up study. The Journal of clinical endocrinology and 
metabolism. Oct 2008;93(10):3943-3949. 
14. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin 
JA. High prevalence of BRAF mutations in thyroid cancer: genetic 
evidence for constitutive activation of the RET/PTC-RAS-BRAF 
signaling pathway in papillary thyroid carcinoma. Cancer research. 
Apr 01 2003;63(7):1454-1457. 
15. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary 
thyroid carcinoma. Journal of the National Cancer Institute. Apr 16 
2003;95(8):625-627. 
16. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and 
RET/PTC rearrangements are alternative events in the 
etiopathogenesis of PTC. Oncogene. Jul 17 2003;22(29):4578-4580. 
17. Ricarte-Filho JC, Li S, Garcia-Rendueles ME, et al. Identification of 
kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid 
cancers. The Journal of clinical investigation. Nov 
2013;123(11):4935-4944. 
18. Kim MH, Bae JS, Lim DJ, et al. Quantification of BRAF V600E 
alleles predicts papillary thyroid cancer progression. Endocrine-
related cancer. 2014;21(6):891-902. 
19. Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a 
prospective cohort study of 5583 cases of thyroid carcinoma treated 
in the united states during 1996. U.S. and German Thyroid Cancer 
Study Group. An American College of Surgeons Commission on 
Cancer Patient Care Evaluation study. Cancer. Jul 01 
2000;89(1):202-217. 
20. Song YS, Lim JA, Min HS, et al. Changes in the clinicopathological 
characteristics and genetic alterations of follicular thyroid cancer. 
European journal of endocrinology. Sep 01 2017. 
21. Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated 
thyroid carcinoma: the Turin proposal for the use of uniform 
diagnostic criteria and an algorithmic diagnostic approach. The 
American journal of surgical pathology. Aug 2007;31(8):1256-1264. 
22. Landa I, Ganly I, Chan TA, et al. Frequent somatic TERT promoter 
mutations in thyroid cancer: higher prevalence in advanced forms of 
 48 
the disease. The Journal of clinical endocrinology and metabolism. 
Sep 2013;98(9):E1562-1566. 
23. Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations 
are a major indicator of poor outcome in differentiated thyroid 
carcinomas. The Journal of clinical endocrinology and metabolism. 
May 2014;99(5):E754-765. 
24. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, 
and cancer stem cells. Nature. Nov 01 2001;414(6859):105-111. 
25. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and 
transcriptional profiling of human mammary stem/progenitor cells. 
Genes & development. May 15 2003;17(10):1253-1270. 
26. Gupta R, Vyas P, Enver T. Molecular targeting of cancer stem cells. 
Cell stem cell. Aug 07 2009;5(2):125-126. 
27. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell. Nature 
medicine. Jul 1997;3(7):730-737. 
28. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke 
MF. Prospective identification of tumorigenic breast cancer cells. 
Proceedings of the National Academy of Sciences of the United States 
of America. Apr 01 2003;100(7):3983-3988. 
29. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer 
cell capable of initiating tumour growth in immunodeficient mice. 
Nature. Jan 04 2007;445(7123):106-110. 
30. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and 
expansion of human colon-cancer-initiating cells. Nature. Jan 04 
2007;445(7123):111-115. 
31. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain 
tumour initiating cells. Nature. Nov 18 2004;432(7015):396-401. 
32. Todaro M, Iovino F, Eterno V, et al. Tumorigenic and metastatic 
activity of human thyroid cancer stem cells. Cancer research. Nov 01 
2010;70(21):8874-8885. 
33. Pilotti S, Collini P, Manzari A, Marubini E, Rilke F. Poorly 
differentiated forms of papillary thyroid carcinoma: distinctive 
entities or morphological patterns? Seminars in diagnostic pathology. 
Aug 1995;12(3):249-255. 
34. Lohberger B, Rinner B, Stuendl N, et al. Aldehyde dehydrogenase 1, 
a potential marker for cancer stem cells in human sarcoma. PloS one. 
2012;7(8):e43664. 
35. Aratake Y, Nomura H, Kotani T, et al. Coexistent anaplastic and 
differentiated thyroid carcinoma: an immunohistochemical study. 
American journal of clinical pathology. Mar 2006;125(3):399-406. 
 49 
36. Shimamura M, Nagayama Y, Matsuse M, Yamashita S, Mitsutake N. 
Analysis of multiple markers for cancer stem-like cells in human 
thyroid carcinoma cell lines. Endocrine journal. 2014;61(5):481-490. 
37. Ke CC, Liu RS, Yang AH, et al. CD133-expressing thyroid cancer 
cells are undifferentiated, radioresistant and survive radioiodide 
therapy. European journal of nuclear medicine and molecular 
imaging. Jan 2013;40(1):61-71. 
38. Zheng X, Cui D, Xu S, Brabant G, Derwahl M. Doxorubicin fails to 
eradicate cancer stem cells derived from anaplastic thyroid carcinoma 
cells: characterization of resistant cells. International journal of 
oncology. Aug 2010;37(2):307-315. 
39. Yun JY, Kim YA, Choe JY, et al. Expression of cancer stem cell 
markers is more frequent in anaplastic thyroid carcinoma compared to 
papillary thyroid carcinoma and is related to adverse clinical 
outcome. Journal of clinical pathology. Feb 2014;67(2):125-133. 
40. Zhu Z, Hao X, Yan M, et al. Cancer stem/progenitor cells are highly 
enriched in CD133+CD44+ population in hepatocellular carcinoma. 
International journal of cancer. May 01 2010;126(9):2067-2078. 
41. Lan L, Luo Y, Cui D, et al. Epithelial-mesenchymal transition 
triggers cancer stem cell generation in human thyroid cancer cells. 
International journal of oncology. Jul 2013;43(1):113-120. 
42. Yasui K, Shimamura M, Mitsutake N, Nagayama Y. SNAIL induces 
epithelial-to-mesenchymal transition and cancer stem cell-like 
properties in aldehyde dehydroghenase-negative thyroid cancer cells. 
Thyroid : official journal of the American Thyroid Association. Aug 
2013;23(8):989-996. 
43. Visciano C, Liotti F, Prevete N, et al. Mast cells induce epithelial-to-
mesenchymal transition and stem cell features in human thyroid 
cancer cells through an IL-8-Akt-Slug pathway. Oncogene. Oct 01 
2015;34(40):5175-5186. 
44. Ahn SH, Henderson YC, Williams MD, Lai SY, Clayman GL. 
Detection of thyroid cancer stem cells in papillary thyroid carcinoma. 
The Journal of clinical endocrinology and metabolism. Feb 
2014;99(2):536-544. 
45. Okamoto M, Hayase S, Miyakoshi M, Murata T, Kimura S. Stem cell 
antigen 1-positive mesenchymal cells are the origin of follicular cells 
during thyroid regeneration. PloS one. 2013;8(11):e80801. 
46. Chin AR, Wang SE. Cytokines driving breast cancer stemness. 
Molecular and cellular endocrinology. Jan 25 2014;382(1):598-602. 
47. Yao S, Graham K, Shen J, et al. Genetic variants in microRNAs and 
breast cancer risk in African American and European American 
women. Breast cancer research and treatment. Oct 2013;141(3):447-
459. 
 50 
48. Borrello MG, Alberti L, Fischer A, et al. Induction of a 
proinflammatory program in normal human thyrocytes by the 
RET/PTC1 oncogene. Proceedings of the National Academy of 
Sciences of the United States of America. Oct 11 
2005;102(41):14825-14830. 
49. Puxeddu E, Knauf JA, Sartor MA, et al. RET/PTC-induced gene 
expression in thyroid PCCL3 cells reveals early activation of genes 
involved in regulation of the immune response. Endocrine-related 
cancer. Jun 2005;12(2):319-334. 
50. Liotti F, Collina F, Pone E, et al. Interleukin-8, but not the Related 
Chemokine CXCL1, Sustains an Autocrine Circuit Necessary for the 
Properties and Functions of Thyroid Cancer Stem Cells. Stem cells. 
Jan 2017;35(1):135-146. 
51. Chiou SH, Yu CC, Huang CY, et al. Positive correlations of and 
Nanog in oral cancer stem-like cells and high-grade oral squamous 
cell carcinoma. Clinical cancer research : an official journal of the 
American Association for Cancer Research. Jul 01 
2008;14(13):4085-4095. 
52. Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell 
characteristics reconstitute the original human tumor in vivo. Cancer 
research. May 15 2007;67(10):4807-4815. 
53. Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem 
cell-like gene expression signature in poorly differentiated aggressive 
human tumors. Nature genetics. May 2008;40(5):499-507. 
54. Wang X, Dai J. Concise review: isoforms of OCT4 contribute to the 
confusing diversity in stem cell biology. Stem cells. May 
2010;28(5):885-893. 
55. Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR. OCT-4, an embryonic 
stem cell marker, is highly expressed in bladder cancer. International 
journal of cancer. Apr 01 2007;120(7):1598-1602. 
56. Ezeh UI, Turek PJ, Reijo RA, Clark AT. Human embryonic stem cell 
genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both 
seminoma and breast carcinoma. Cancer. Nov 15 2005;104(10):2255-
2265. 
57. Koury J, Zhong L, Hao J. Targeting Signaling Pathways in Cancer 
Stem Cells for Cancer Treatment. Stem cells international. 
2017;2017:2925869. 
58. Tang B, Raviv A, Esposito D, et al. A flexible reporter system for 
direct observation and isolation of cancer stem cells. Stem cell 
reports. Jan 13 2015;4(1):155-169. 
59. Kuroda T, Tada M, Kubota H, et al. Octamer and Sox elements are 
required for transcriptional cis regulation of Nanog gene expression. 
Molecular and cellular biology. Mar 2005;25(6):2475-2485. 
 51 
60. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer 
immunoediting: from immunosurveillance to tumor escape. Nature 
immunology. Nov 2002;3(11):991-998. 
61. Swann JB, Smyth MJ. Immune surveillance of tumors. The Journal of 
clinical investigation. May 2007;117(5):1137-1146. 
62. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer 
immunoediting. Annual review of immunology. 2004;22:329-360. 
63. Chaplin DD. Overview of the immune response. The Journal of 
allergy and clinical immunology. Feb 2010;125(2 Suppl 2):S3-23. 
64. Pardoll DM. The blockade of immune checkpoints in cancer 
immunotherapy. Nature reviews. Cancer. Mar 22 2012;12(4):252-
264. 
65. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive 
strategies that are mediated by tumor cells. Annual review of 
immunology. 2007;25:267-296. 
66. Ghebeh H, Sleiman GM, Manogaran PS, et al. Profiling of normal 
and malignant breast tissue show CD44high/CD24low phenotype as a 
predominant stem/progenitor marker when used in combination with 
Ep-CAM/CD49f markers. BMC cancer. Jun 14 2013;13:289. 
67. Schatton T, Murphy GF, Frank NY, et al. Identification of cells 
initiating human melanomas. Nature. Jan 17 2008;451(7176):345-
349. 
68. Chahlavi A, Rayman P, Richmond AL, et al. Glioblastomas induce T-
lymphocyte death by two distinct pathways involving gangliosides 
and CD70. Cancer research. Jun 15 2005;65(12):5428-5438. 
69. El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ 
regulatory T cells in tumor-infiltrating lymphocytes of human 
glioblastoma multiforme. Neuro-oncology. Jul 2006;8(3):234-243. 
70. Akalay I, Janji B, Hasmim M, et al. Epithelial-to-mesenchymal 
transition and autophagy induction in breast carcinoma promote 
escape from T-cell-mediated lysis. Cancer research. Apr 15 
2013;73(8):2418-2427. 
71. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer 
metastasis is accelerated through immunosuppression during Snail-
induced EMT of cancer cells. Cancer cell. Mar 03 2009;15(3):195-
206. 
72. Soldati R, Berger E, Zenclussen AC, et al. Neuroblastoma triggers an 
immunoevasive program involving galectin-1-dependent modulation 
of T cell and dendritic cell compartments. International journal of 
cancer. Sep 01 2012;131(5):1131-1141. 
73. Fan X, Khaki L, Zhu TS, et al. NOTCH pathway blockade depletes 
CD133-positive glioblastoma cells and inhibits growth of tumor 
neurospheres and xenografts. Stem cells. Jan 2010;28(1):5-16. 
 52 
74. Banito A, Gil J. Induced pluripotent stem cells and senescence: 
learning the biology to improve the technology. EMBO reports. May 
2010;11(5):353-359. 
75. Kawamura T, Suzuki J, Wang YV, et al. Linking the p53 tumour 
suppressor pathway to somatic cell reprogramming. Nature. Aug 27 
2009;460(7259):1140-1144. 
76. Wang L, Guo H, Lin C, Yang L, Wang X. Enrichment and 
characterization of cancer stemlike cells from a cervical cancer cell 
line. Molecular medicine reports. Jun 2014;9(6):2117-2123. 
77. Kim DH, Popradi G, Xu W, et al. Peripheral blood eosinophilia has a 
favorable prognostic impact on transplant outcomes after allogeneic 
peripheral blood stem cell transplantation. Biology of blood and 
marrow transplantation : journal of the American Society for Blood 
and Marrow Transplantation. Apr 2009;15(4):471-482. 
78. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal 
transition generates cells with properties of stem cells. Cell. May 16 
2008;133(4):704-715. 
79. Muller M, Hermann PC, Liebau S, et al. The role of pluripotency 
factors to drive stemness in gastrointestinal cancer. Stem cell 
research. Mar 2016;16(2):349-357. 
80. Carina V, Zito G, Pizzolanti G, et al. Multiple pluripotent stem cell 
markers in human anaplastic thyroid cancer: the putative upstream 
role of SOX2. Thyroid : official journal of the American Thyroid 
Association. Jul 2013;23(7):829-837. 
81. Zhong F, Cheng X, Sun S, Zhou J. Transcriptional activation of PD-
L1 by SOX2 contributes to the proliferation of hepatocellular 
carcinoma cells. Oncology reports. May 2017;37(5):3061-3067. 
82. Almozyan S, Colak D, Mansour F, et al. PD-L1 promotes OCT4 and 
Nanog expression in breast cancer stem cells by sustaining 
PI3K/AKT pathway activation. International journal of cancer. Oct 
01 2017;141(7):1402-1412. 
 
 
 
